Cargando…

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sebio, A., Stintzing, S., Heinemann, V., Sunakawa, Y., Zhang, W., Ichikawa, W., Tsuji, A., Takahashi, T., Parek, A., Yang, D., Cao, S., Ning, Y., Stremitzer, S., Matsusaka, S., Okazaki, S., Barzi, A., Berger, M., Lenz, H-J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378677/ https://www.ncbi.nlm.nih.gov/pubmed/27698403 http://dx.doi.org/10.1038/tpj.2016.69

Ejemplares similares

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023)

mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022)

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
por: Zheng, Peng, et al.
Publicado: (2018)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer
por: Sebio, Ana, et al.
Publicado: (2015)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018)

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
por: Marmorino, Federica, et al.
Publicado: (2019)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
por: Chen, Hong-Hwa, et al.
Publicado: (2021)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
por: Kimura, Yutaka, et al.
Publicado: (2017)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC)
por: Tysarowski, Andrzej, et al.
Publicado: (2018)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
por: Argiles, Guillem, et al.
Publicado: (2019)

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
por: Modest, Dominik Paul, et al.
Publicado: (2020)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
por: Bahl, Ankur, et al.
Publicado: (2020)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
por: Zhang, Yiyi, et al.
Publicado: (2021)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
por: Yasui, H., et al.
Publicado: (2023)

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study
por: Kodera, Yasuhiro, et al.
Publicado: (2023)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
por: Feliu, J, et al.
Publicado: (2014)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial
por: Ferreira, Cláudia S., et al.
Publicado: (2023)

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
por: Lowe, Kimberly A., et al.
Publicado: (2019)

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
por: Sunakawa, Y., et al.
Publicado: (2022)

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy
por: Quirino, Michela, et al.
Publicado: (2017)

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
por: Gmeiner, William H
Publicado: (2021)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
por: Volz, Nico B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_17dcmp2lbhqd14chm5orfdrnmq